There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on ACADIA Pharmaceuticals (ACAD) and Amgen (AMGN) with bullish sentiments.
ACADIA Pharmaceuticals (ACAD)
In a report released today, Jeffrey Hung from Morgan Stanley maintained a Buy rating on ACADIA Pharmaceuticals, with a price target of $60.00. The company’s shares closed last Wednesday at $53.31.
According to TipRanks.com, Hung is a 5-star analyst with an average return of 40.5% and a 66.7% success rate. Hung covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Prelude Therapeutics, and Repare Therapeutics.
ACADIA Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $59.60, implying a 12.1% upside from current levels. In a report issued on December 14, J.P. Morgan also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
Amgen (AMGN)
In a report released today, Matthew Harrison from Morgan Stanley maintained a Buy rating on Amgen, with a price target of $276.00. The company’s shares closed last Wednesday at $229.50.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 22.2% and a 62.6% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Biohaven Pharmaceutical Holding Co, Global Blood Therapeutics, and Zentalis Pharmaceuticals.
Currently, the analyst consensus on Amgen is a Moderate Buy with an average price target of $261.05, implying a 13.5% upside from current levels. In a report issued on December 8, Piper Sandler also maintained a Buy rating on the stock with a $280.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on AMGN:
